Epidemiology of chronic myeloid leukaemia: an update

Abstract

National and regional population-based registries are, provided diagnostic accuracy and full coverage of the target population, indispensible tools for epidemiological research. Chronic myeloid leukaemia (CML) registries with more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7-1.0/100,000, a median age at diagnosis of 57-60 years and a male/female ratio of 1.2-1.7. The incidence of CML has been stable over time. Worldwide, variations in the reported incidence of CML may be due to methodological issues, but a true difference between different geographical areas and/or ethnical subgroups cannot be excluded. The prevalence of CML is not well known but has been estimated to be 10-12/100,000 inhabitants with a steady increase due to the dramatic improvement in survival of these patients. In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased. The importance of socio-economic factors and health-care setting for outcome and the possible increased risk of secondary cancer in CML are areas of ongoing research.

Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study

“…Chronic myeloid leukemia (CML) is a rare type of cancer that occurs in 0.7–1.8 per 100,000 population annually 1. Owing to effective treatment with tyrosine kinase inhibitors (TKIs), CML has become a chronic disease with a rising prevalence globally, expected to plateau at 35 times its annual incidence by 2050 1.…”

“…Owing to effective treatment with tyrosine kinase inhibitors (TKIs), CML has become a chronic disease with a rising prevalence globally, expected to plateau at 35 times its annual incidence by 2050 1. In Malaysia, ~740 new cases of leukemia are diagnosed annually,2 of which CML accounts for 15%.…”

Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

“…Для проведения исследования анализу подвергнуты амбулаторные карты, истории болезни 208 больных ХМЛ, наблюдавшихся в консультативно-поликлини-ческом от делении гематологии ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» (ФГБУ РосНИИГТ ФМБА) с 2003 по 2015 г. Для сравнения были использованы опубли-кованные результаты многоцентровых клинических ис-следований по применению ингибиторов тирозинкиназ при ХМЛ [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Изучали первичную заболеваемость и распространенность ХМЛ, результаты таргетной терапии ХМЛ первой и последующих линий.…”

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

“…2 Long-term survival of CP-CML patients who were in stable disease remission (complete cytogenetic response [CCyR]) and in treatment with imatinib was shown to be not statistically different from that of the general population. 3 Presently, published evidence-based guidelines for the management of CML recommend initial treatment with any frontline-approved TKI (ie, imatinib, nilotinib, or dasatinib) and lifelong TKI treatment in cases of optimal response in routine practice.…”